Novartis’s Pluvicto (radioligand therapy) is now FDA Approved for mCRPC treatment
The Swiss based Pharma Major scores yet another FDA approval for its new radioligand therapy. This much anticipated regulatory nod was received this week, enabling the global innovator to offer a new treatment paradigm. mCRPC is the short form for metastatic castration resistant prostate cancer. Prostate cancer is the most common cancer type in men….
News Views